Short with tight stop if it reaches the arrowed line and does not close above it. This line will then become the stop.
Take profit at the lower red line
NASDAQ:SEEL
-EMA21 cross below EMA 50
-Price breached support level 1
-Price breached support level 2
-Radar: Possible pullback or continue down, watch for price to fall below SMA200.
SEEL Seelos Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders.
On 3/14/2022 B. Riley Lower Price Target Buy rating for SEEl from $6.00 to $4.00.
52 Week Range 0.76 - 6.60
Is this a strong buy? Looking...
SEEL: Seelos Therapeutics, Inc.
2021-11-08 08:00:00
Seelos Therapeutics Announces FDA Acceptance of Investigational New Drug Application and Grant of Fast Track Designation for SLS-005 (IV Trehalose) for the Treatment of Spinocerebellar Ataxia
The price tested the 200 sma and bounced. The current price is just bellow the POC (YTD). The divergence between the price and the MFI is a bullish signal.
Like this set up for a long swing trade. Targeting: $4.29, $6.60 in the short-midterm.
My favorite new indie stock, Seelos Therapeutics, was recently upgraded from a price target of $4.70 to a whopping $15.
For this to happen, it may have to beat some bears (in SPY) and sharks (in short interest).
Short interest in the stock is down, with most shares not available to short. This is positive and bullish for shorter term.
The stock market looks to...
Daily Chart:
Here I will look at the overall picture of this stock and identify what stage the market is in. This will determine whether I will be Long, Short, or staying out of the trade.
The Picture is clear as day, we are currently in an Uptrend. After a lengthy Downtrend, the stock went into an Accumulation and broke out upwards on 12/21/2020. Price has since...
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel technologies and therapeutics for the treatment of the central nervous system, respiratory, and other disorders.
Bullish Pennant (62%)
Pros:
Volume during post formation
Descending volume during triangle formation
PPS above 50MA and 200MA
RS above 0 and ascending
R/R ratio above 4
250RSI above 50 but flat
200MA ascending
Cons:
ATR Flat
May fill gap back down to 3.15$
Target:
PT = 6.96$
Help how ever you can to keep this alive.
Thank you to those who have donated...
Shares of $SEEL skyrocketed today after BTIG initiated coverage on the stock with a buy recommendation and a one-year price target nearly 4.7 times higher than Seelos' closing price on Thursday.
BTIG analyst Robert Hazlett likes the prospects for Seelos' pipeline. Last week, the biotech announced that it had completed enrollment in a pivotal proof-of-concept...
